Skip to content

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

TEVA TEVJF

CIK 0000818686

← back to feed
Revenue (TTM)
$16.53B
+4.3% YoY Q1 Mar 2026
Net Income (TTM)
$1.3B
+186.0% YoY Q1 Mar 2026
EPS Diluted (TTM)
$1.10
+183.4% YoY Q1 Mar 2026
Gross Margin
49.9%
Q1 Mar 2026
Operating Margin
15.2%
Q1 Mar 2026
Net Margin
7.9%
Q1 Mar 2026
Free Cash Flow (TTM)
−$91M
Q1 Mar 2026
Cash
$3.74B
Q1 Mar 2026
Total Debt
$28.83B
Q1 Mar 2026
Shares Outstanding
1.16B sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings